XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Colorectal Neoplasms
  • Liver Neoplasms

abstract

  • Updated survival data from study NO16966 show that XELOX is similar to FOLFOX4, confirming the primary analysis of progression-free survival. XELOX can be considered as a routine first-line treatment option for patients with metastatic colorectal cancer.

publication date

  • June 28, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3137415

Digital Object Identifier (DOI)

  • 10.1038/bjc.2011.201

PubMed ID

  • 21673685

Additional Document Info

start page

  • 58

end page

  • 64

volume

  • 105

number

  • 1